Dr.Deepak Choudhury

Dr.NIKITA DASH, Dr.Ashwini Meherda

Abstract

Aim: To study factors influencing frequency of intravitreal ranibizumab injections required in CSME. Methods: Prospective interventional study of 1 year (April 2018 – March2019) done on 145 type-2 diabetic patients with CSME. IO & OCT done. Blood sugar, HbA1c, serum urea, creatinine & lipid profile done. BCVA, central macular thickness (CMT) were noted prior to injection and 1 week, 1, 2 , 6 month following injections. Intravitreal ranibizumab (0.5mg/0.05ml) injections given. Results: Average age 57.2±11.9 years. Male to female ratio 4:1. On presentation BCVA was <6/60 in 30, 6/60-6/36 in 106 & Mean CMT 503±89.6μ. Mean CMT - 384.8±98.3 μ, 351.1±97.9 μ, 301.9±98.4μ and 253.3±78.7μ at 1 week, 1, 3 & 6 month (p<0.05). >1 injection required in mean serum urea of 29.22±20.32, creatinine of 1.13±0.77 & HbA1c of 9.98±0.53. Final BCVA improved to 6/9 in 14, 6/12 in 62, 6/18 in 42 cases. Conclusion: Patients with increased serum urea-creatinine and HbA1c levels require multiple injections.